Fibromyalgia medical therapy

Revision as of 15:39, 24 November 2017 by Badgettrg (talk | contribs) (→‎Vitamin D)
Jump to navigation Jump to search

Fibromyalgia Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Fibromyalgia from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Criteria

History and Symptoms

Physical Examination

Laboratory Findings

X Ray

CT

MRI

Ultrasound

Other Diagnostic Studies

Other Imaging Findings

Treatment

Medical Therapy

Psychotherapy

Surgery

Primary Prevention

Secondary Prevention

Future or Investigational Therapies

Case Studies

Case #1

Fibromyalgia medical therapy On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Fibromyalgia medical therapy

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Fibromyalgia medical therapy

CDC on Fibromyalgia medical therapy

Fibromyalgia medical therapy in the news

Blogs on Fibromyalgia medical therapy

Directions to Hospitals Treating Fibromyalgia

Risk calculators and risk factors for Fibromyalgia medical therapy

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] ; Associate Editor(s)-in-Chief: Aditya Ganti M.B.B.S. [2]

Overview

There is no universally accepted treatment for fibromyalgia. Treatment typically consists of symptomic management and the treatment options include medications and cognitive behavioral therapy, which has been shown to be effective in alleviating pain and other fibromyalgia-related symptoms.

Medical Therapy

The medical therapy for fibromyalgia includes analgesics, antidepressants, skeletal muscle relaxants, anticonvulsants, and anti-anxiety medications.[1]

Single agent therapy

  • Preferred regimen (1): Amitriptyline 10-70 mg orally once daily at bedtime
  • Preferred regimen (2): Cyclobenzaprine 5-30 mg orally once daily at bedtime
  • Preferred regimen (3): Duloxetine 30-60 mg orally once daily
  • Preferred regimen (4): Milnacipran 12.5 mg orally once daily initially, followed by 12.5 mg twice daily for 2 days, followed by 25 mg twice daily for 4 days, then 50-100 mg twice daily thereafter
  • Preferred regimen (5): Pregabalin 75-225 mg orally twice daily, maximum 450 mg/day

Combination Therapy

  • Preferred regimen (1): Amitriptyline 10-70 mg orally once daily at bedtime (OR)
  • Preferred regimen (2): Cyclobenzaprine 5-30 mg orally once daily at bedtime

AND

  • Preferred regimen (3): Duloxetine 30-60 mg orally once daily; higher doses have been used, consult a specialist for guidance (OR)
  • Preferred regimen (4): Milnacipran 12.5 mg orally once daily initially, followed by 12.5 mg twice daily for 2 days, followed by 25 mg twice daily for 4 days, then 50-100 mg twice daily thereafter

AND

  • Preferred regimen (5): Pregabalin 75-225 mg orally twice daily, maximum 450 mg/day (OR)
  • Preferred regimen (6): Gabapentin 300 mg orally once daily on the first day, followed by 300 mg twice daily on the second day, followed by 300 mg three times daily on the third day, then titrate dose according to response up to 1800-2400 mg/day given in 3 divided doses

Underlying randomized studies of treatment

Vitamin D

Although initial studies suggest that low vitamin D levels may be associated with nonspecific musculoskeletal pain[2]; more recent studies make this doubtful.[3][4]

Trials conflict whether Vitamin D is beneficial[4][3].

  • Benefit was found in trials that were not prospectively registered[5][6].

A meta-analysis concludes that Vitamin D reduces pain[7].

References

  1. Selfridge, Dr. Nancy, and Peterson, Franklynn (2001). Freedom from Fibromyalgia: The 5-Week Program Proven to Conquer Pain. ISBN 0-8129-3375-3.
  2. Plotnikoff GA, Quigley JM (2003). "Prevalence of severe hypovitaminosis D in patients with persistent, nonspecific musculoskeletal pain". Mayo Clin. Proc. 78 (12): 1463–70. PMID 14661675.
  3. 3.0 3.1 Warner AE, Arnspiger SA (2008). "Diffuse musculoskeletal pain is not associated with low vitamin D levels or improved by treatment with vitamin D". J Clin Rheumatol. 14 (1): 12–6. doi:10.1097/RHU.0b013e31816356a9. PMID 18431091. Unknown parameter |month= ignored (help)
  4. 4.0 4.1 Arvold DS, Odean MJ, Dornfeld MP, Regal RR, Arvold JG, Karwoski GC; et al. (2009). "Correlation of symptoms with vitamin D deficiency and symptom response to cholecalciferol treatment: a randomized controlled trial". Endocr Pract. 15 (3): 203–12. PMID 19364687.
  5. Wepner F, Scheuer R, Schuetz-Wieser B, Machacek P, Pieler-Bruha E, Cross HS; et al. (2014). "Effects of vitamin D on patients with fibromyalgia syndrome: a randomized placebo-controlled trial". Pain. 155 (2): 261–8. doi:10.1016/j.pain.2013.10.002. PMID 24438771.
  6. Yilmaz R, Salli A, Cingoz HT, Kucuksen S, Ugurlu H (2016). "Efficacy of vitamin D replacement therapy on patients with chronic nonspecific widespread musculoskeletal pain with vitamin D deficiency". Int J Rheum Dis. 19 (12): 1255–1262. doi:10.1111/1756-185X.12960. PMID 27860257.
  7. Yong WC, Sanguankeo A, Upala S (2017). "Effect of vitamin D supplementation in chronic widespread pain: a systematic review and meta-analysis". Clin Rheumatol. 36 (12): 2825–2833. doi:10.1007/s10067-017-3754-y. PMID 28812209.